Physician profile
Heather Baugh
NPI 1649653668
$6,267.56
in general payments reported to CMS, 2019-2025
19 companies · $2,030 in 2025
The $2,030 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $50.98 · 2022: $131 · 2023: $1,987 · 2024: $2,068 · 2025: $2,030.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,085.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,085.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,188.21 | 2023-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $857.36 | 2023-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $724.05 | 2022-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Lundbeck LLC | $608.59 | 2023-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $529.10 | 2023-2025 | Ingrezza |
| Axsome Therapeutics, INC. | $435.94 | 2023-2025 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $364.62 | 2023-2025 | Austedo Xr, Uzedy, Austedo Xr |
| E.R. Squibb & Sons, L.L.C. | $297.61 | 2024-2025 | Cobenfy |
| Vanda Pharmaceuticals INC. | $253.96 | 2022-2025 | Fanapt |
| Janssen Pharmaceuticals, INC | $243.54 | 2023-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Corium, LLC | $186.89 | 2023 | Azstarys |
| Alkermes, INC. | $186.20 | 2023-2025 | Aristada, Lybalvi, Vivitrol |
| Takeda Pharmaceuticals U.S.A., INC. | $181.84 | 2023-2025 | Trintellix |
| Indivior INC. | $62.38 | 2023-2024 | Sublocade |
| Abbott Laboratories | $50.98 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $33.30 | 2023-2025 | Loreev Xr, Sertraline Hcl |
| Supernus Pharmaceuticals, INC. | $30.33 | 2023-2025 | Qelbree, Qelbree |
| Harmony Biosciences LLC | $17.52 | 2024 | |
| Idorsia Pharmaceuticals US INC | $15.14 | 2024 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Baugh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.